Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
TScan Therapeutics's operating assets for the quarter that ended in Jun. 2026 was $71.30 Mil. TScan Therapeutics's operating liabilities for the quarter that ended in Jun. 2026 was $11.54 Mil. TScan Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $201.99 Mil. Therefore, TScan Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was 0.30.
TScan Therapeutics Scaled Net Operating Assets Related Terms
TScan Therapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for TScan Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TScan Therapeutics Scaled Net Operating Assets Chart
TCRX vs MCRB, HYPD, ELOX: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, TScan Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TScan Therapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.30 mean?
TScan Therapeutics (TCRX) has a Scaled Net Operating Assets of 0.30 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on TScan Therapeutics and its competitors.
Is TScan Therapeutics' Scaled Net Operating Assets too high?
TScan Therapeutics' current Scaled Net Operating Assets is 0.30. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Scaled Net Operating Assets compare to MCRB and HYPD?
TScan Therapeutics' Scaled Net Operating Assets of 0.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on TScan Therapeutics and its competitors. TScan Therapeutics's current Scaled Net Operating Assets is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.73 — trading 44.7% below its estimated fair value. The current Scaled Net Operating Assets is 0.30. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Scaled Net Operating Assets is 0.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TScan Therapeutics (TCRX) Overvalued in 2026?
Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued.
The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32.
GuruFocus considers TScan Therapeutics to be Possible Value Trap.
Key valuation signals for TCRX:
Scaled Net Operating Assets: 0.30
GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score
Get the complete analysis for TCRX
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRX has been successfully added to your 
